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ABSTRACT 
Standard treatment regimens consisting of surgery, radiation and chemotherapy have proven 
ineffective for the treatment of high-grade gliomas such as glioblastoma multiforme (GBM). An 
effective cure requires elimination of nests of tumor cells that have migrated from the resection 
margin and infiltrated normal brain. A number of localized therapies, including light-based 
approaches such as photodynamic therapy (PDT) and photochemical internalization (PCI) are 
currently under investigation for the management of GBM patients.  
Several studies have demonstrated a high degree of synergy between PDT and bleomycin, via the 
PCI mechanism, in a variety of in vitro and in vivo models, including glioma cell lines. The purpose 
of this study was to examine the efficacy of combined treatments consisting of PDT and the 
chemotherapeutic agent, 5-fluorouracil (5-FU) in a 3-dimensional spheroid model consisting of 
F98 rat glioma cells. Spheroids were incubated with a photosensitizer (aluminum phthalocyanine 
disulfonate; AlPcS2a) and irradiated with 670 nm laser light. Three different wash protocols (0, 4 
and 24 h) were employed to determine whether any observed interactions between PDT and 5-FU 
could be attributed to the PCI mechanism, or were simply due to different cytotoxic pathways of 
the two treatment modalities.  
Although the combined PDT + 5-FU treatments resulted in greater suppression of spheroid growth 
compared to either treatment alone, no statistically significant differences in growth effects were 
observed between 0 and 4 h wash protocols suggesting that the combined treatment effects were 
due to different mechanisms of cytotoxicity, rather than a PCI effect. 
iv 
 
ACKNOWLEDGEMENTS 
 
To begin, I express my complete appreciation to my thesis advisor, Dr. Steen Madsen, for his 
assistance and knowledge in the development and understanding of the fields of study involved 
my research project. 
 I also express gratitude to Kevin Ashi and Charles Bynum for their time and help in the lab with 
various aspects regarding my project. I am also very grateful for the assistance of Stephanie 
Molina, who taught me lab protocols and provided support with other topics. I also like to thank 
my family for their strength throughout my entire studies.  
Lastly, I want to thank Heena Kumar and Gregory Sobczyk for the valuable advice and 
encouragement throughout my master’s studies and thesis project. 
 
  
v 
 
 
  TABLE OF CONTENTS 
ABSTRACT ................................................................................................................................... iii 
ACKNOWLEDGEMENTS ........................................................................................................... iv 
LIST OF TABLES ........................................................................................................................ vii 
LIST OF FIGURES ..................................................................................................................... viii 
INTRODUCTION .......................................................................................................................... 1 
1.1 Glioblastoma Multiforme .......................................................................................................... 1 
1.2 Photodynamic Therapy ............................................................................................................. 3 
1.3 The use of PDT for the treatment of brain tumors .................................................................... 6 
1.4 Photochemical Internalization .................................................................................................. 7 
1.5 Cell line ..................................................................................................................................... 9 
1.6 Spheroids................................................................................................................................... 9 
1.7 5-Fluorouracil ......................................................................................................................... 11 
1.8 Photosensitizer ........................................................................................................................ 12 
1.9 Scope of Work ........................................................................................................................ 13 
MATERIALS AND METHODS .................................................................................................. 14 
2.1 Maintenance of Cell Line ........................................................................................................ 14 
2.2 Creation of Spheroids ............................................................................................................. 14 
2.3 5-FU Procedure ....................................................................................................................... 15 
2.4 Laser Setup.............................................................................................................................. 15 
2.5 Photodynamic Therapy Procedure .......................................................................................... 16 
2.6 Combined PDT + 5-FU Procedure ......................................................................................... 17 
2.7 Measurements and Analysis ................................................................................................... 18 
RESULTS ..................................................................................................................................... 19 
3.1 5-FU dose dependence ............................................................................................................ 19 
3.2 PDT results.............................................................................................................................. 19 
3.3 PDT + 5-FU results ................................................................................................................. 22 
DISCUSSION ............................................................................................................................... 25 
CONCLUSIONS........................................................................................................................... 28 
REFERENCES ............................................................................................................................. 29 
CURRICULUM VITAE ............................................................................................................... 35 
vi 
 
 
  
vii 
 
LIST OF TABLES 
 
Table 1 Incidence rates of CNS tumors.. ........................................................................................ 2 
Table 2 One- and five-year relative survival rates. ......................................................................... 3 
Table 3 Summary of macromolecules used in PCI. ........................................................................ 8 
Table 4 Evaluation of statistical significance for different wash protocols .................................. 20 
Table 5 Alpha values for different wash protocols ....................................................................... 22 
 
  
viii 
LIST OF FIGURES 
Figure 1 Overview of PDT (Godfrey 2018) ................................................................................... 4 
Figure 2 PDT toxicity via generation of oxygen radicals (Joy et al. 2014) . .................................. 4 
Figure 3 PDT-induced types of cell death (Abrahamse and Hamblin, 2016). ................................ 5 
Figure 4 The PCI process (Weyergang et al. 2017). ....................................................................... 7 
Figure 5 F98 rat glioma cells (ATCC 2016). .................................................................................. 9 
Figure 6 Three-dimensional spheroid consisting of F98 cells illustrating the characteristic cell 
viability zones ............................................................................................................................... 10 
Figure 7 Molecular structure of 5-FU (Zhang et al. 2015). .......................................................... 12 
Figure 8 Molecular structure of AlPcS2a (Selbo et al. 2002). ...................................................... 12 
Figure 9 Experimental setup showing laser irradiation of 96-well plate. ..................................... 16 
Figure 10 Effects of 5-FU on F98 spheroid growth. ..................................................................... 19 
Figure 11 PDT effects on F98 glioma spheroids subjected to three different wash protocols.. ... 21 
Figure 12 Effects of combined PDT and 5-FU on F98 glioma spheroids. ................................... 23 
Figure 13 Growth kinetics of F98 glioma spheroids.. .................................................................. 24 
1 
INTRODUCTION 
1.1 Glioblastoma Multiforme  
High-grade brain tumors such as glioblastoma multiforme (GBM) originate from glial cells located 
in the central nervous system (CNS). CNS tumors are relatively rare accounting for only about 2% 
of all cancer deaths (Chandana et al. 2008). GBM is the most common type of glioma accounting 
for approximately 50% of all gliomas and 15.6% of all primary brain tumors (Table 1). Due to 
their aggressive and infiltrative nature, GBMs are one of the most deadly types of cancer with one 
and five-year survival rates of 35% and 4.7%, respectively (Table 2). A variety of GBM subgroups 
exist but the most aggressive is also the most commonly seen in humans (Holland 2000). Due to 
the poor prognosis and limited efficacy of current treatments, significant efforts have been devoted 
to develop alternative treatments including the use of hybrid viruses, gene therapy and a wide 
variety of immunotherapeutic approaches (Holland 2000). GBMs pose significant therapeutic 
challenges due to a number of factors including their heterogeneity (multiforme) and invasive 
behavior. The tumors consist of both rapidly propagating cells as well as regions of necrosis. 
Numerous genetic alterations are associated with GBM including mutations in the epidermal 
growth factor receptor (EGFR) and phosphatase and tensin homolog (PTEN) (Alifieris and 
Trafalis 2015). The collective effect of these mutations is to disrupt the cell cycle resulting in 
uncontrollable cell division.  
The primary treatment for GBM is surgical resection with the aim of removing as much of the 
tumor as possible. Unfortunately, due to the infiltration of glioma cells into normal brain, surgery 
is not sufficient to eradicate the disease. A complicating factor for achieving complete resection is 
the inability to visualize infiltrating glioma cells with current imaging modalities such as magnetic 
resonance imaging. Secondary treatments involving radiation and chemotherapy are typically used 
in an attempt to eradicate infiltrating glioma cells however, as evidenced from high recurrence 
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rates, these treatments are ineffective thus providing the rationale for alternative localized 
treatment approaches, including light-based techniques such as photochemical internalization 
(PCI) aimed at eliminating infiltrating cells in normal brain.  
 
 
 
Histology Total 
  
N 
% of All 
Tumors 
Median 
Age 
Rate 
Tumors of Neuroepithelial Tissue 101,825 31.2 56 6.60 
 Pilocytic astrocytoma 4,741 1.5 13 0.33 
 Diffuse astrocytoma 8,535 2.6 47 0.56 
 Anaplastic astrocytoma 5,621 1.7 54 0.37 
 Glioblastoma 50,872 15.6 64 3.19 
 Oligodendroglioma 4,020 1.2 43 0.27 
 Ependymal tumors 6,304 1.9 44 0.42 
 Glioma malignant, NOS 6,765 2.1 38 0.46 
 Neuronal and mixed neuronal-glial 
tumors 
4,036 1.2 27 0.27 
 Embryonal tumors 3,790 1.2 9 0.26 
Tumors of Cranial and Spinal Nerves 26,564 8.1 55 1.69 
 Nerve sheath tumors 26,548 8.1 55 1.69 
Tumors of Meninges 121,110 37.1 65 7.71 
 Meningioma 116,986 35.8 65 7.44 
Lymphomas and Hemopoietic 
Neoplasms 
7,122 2.2 65 0.46 
 Lymphoma 6,919 2.1 65 0.44 
Germ Cell Tumors and Cysts 1,464 0.4 17 0.10 
Tumors of Sellar Region 50,709 15.5 50 3.32 
 Tumors of the pituitary 47,958 14.7 51 3.13 
Unclassified Tumors 17,917 5.5 64 1.16 
 Hemangioma 3,934 1.2 49 0.26 
 Neoplasm, unspecified 13,895 4.3 70 0.90 
TOTAL‡ 326,711 100 59 21.03 
Table 1 Incidence rates of CNS tumors. Rates are per 100,000 and are age-adjusted to the 2000 U.S. standard population (Ostrom 
et al. 2013). 
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Histology N 1-Yr 5-Yr 
    % % 
Pilocytic astrocytoma 3,301 97.9 94.4 
Diffuse astrocytoma 5,902 71.3 47.3 
Anaplastic astrocytoma 3,472 60.1 26.5 
Glioblastoma 28,212 35.0 4.7 
Oligodendroglioma 3,226 93.8 79.1 
Anaplastic oligodendroglioma 1,257 80.6 50.7 
Ependymal tumors 2,517 93.9 83.4 
Oligoastrocytic tumors 1,820 87.2 61.0 
Glioma malignant, NOS 4,014 61.1 43.4 
Neuronal and mixed neuronal-glial tumors 469 90.2 74.5 
Embryonal tumors 2,666 81.5 61.3 
 Medulloblastoma 1,573 88.2 71.1 
 Primative neuroectodermal tumor 651 76.4 49.5 
 Atypical teratoid/rhabdoid tumor 181 48.1 28.0 
 Other embryonal histologies 261 76.3 54.2 
Meningioma 1,099 82.6 64.7 
Lymphoma 4,500 47.6 29.1 
Total: All Brain and Other Nervous System 66,830 56.9 33.8 
Table 2 One- and five-year relative survival rates for selected malignant brain and central nervous system tumors by histology 
(Ostrom et al. 2013). 
1.2 Photodynamic Therapy  
PDT is the use of light and a photosensitizer to cause cell damage (Figure 1). Following 
photosensitizer administration, light of a particular wavelength matching an absorption resonance 
of the photosensitizer, is used to excite the molecule. The excited photosensitizer interacts with 
ground state molecular oxygen resulting in the generation of singlet molecular oxygen, a potent 
reactive oxygen species, resulting in cell death (Figure 2) (Robertson, Evans, and Abrahamse 
2009). Like radiation therapy, PDT is an oxygen-mediated treatment and, as such, efficacy is 
sensitively dependent on the presence of oxygen during treatment.  
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Figure 1 Overview of PDT (Godfrey 2018) 
PDT is somewhat limited by the poor penetration depth of light in biological tissues (typically a 
few mm) and therefore light must be delivered in close proximity to the tumor. This is typically 
accomplished using laser light coupled into optical fibers in contact with or embedded into the 
tumor and, as such, this approach provides a high degree of tumor selectivity which is important 
since most photosensitizers have rather poor specificity (Robertson, Evans, and Abrahamse 2009). 
PDT efficacy depends on a number of factors including photosensitizer type, light dose and dose 
rate, and tissue oxygenation status.  
Figure 2 PDT toxicity via generation of oxygen radicals (Joy et al. 2014) . 
Photosensitizers with strong absorption in the red to near-infrared are desirable since light has 
optimum penetration in biological tissues in this wavelength range. This optical window is due to 
the limited absorption of tissue chromophores in the red to near-infrared region of the 
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electromagnetic spectrum (Chester, Martellucci, and Scheggi 1991). Light delivered at low dose 
rates has been found to be more effective compared to high dose rate PDT in a number of in vitro 
and in vivo models and hence, provides the rationale for the low dose rate used in this work 
(Madsen et al. 2006). High dose rates have been shown to result in photobleaching of the sensitizer 
thus rendering it incapable of producing singlet oxygen – the primary cytotoxic species in PDT. 
From a mechanistic standpoint, PDT has been shown to affect various levels of cell signaling, e.g. 
it can increase the levels of intracellular calcium in cancer cells as well as the level of ceramide, a 
potent inducer of apoptotic cell death. PDT has also been shown to disrupt the epidermal growth 
factor receptor (EGFR) which is known to help tumors proliferate. Transcription factors are also 
affected as well as cytokines, which are proteins that control immune responses and other related 
functions (Robertson, Evans, and Abrahamse 2009).  
 
Figure 3 PDT-induced types of cell death (Abrahamse and Hamblin 2016). 
PDT can induce either apoptosis, autophagy or necrosis depending on a number of factors 
including type of photosensitizer, light dose and dose rate (Figure 3). Unlike ionizing radiation 
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and many chemotherapeutic agents, PDT does not exert its effects via DNA damage (Robertson, 
Evans, and Abrahamse 2009).  
1.3 The use of PDT for the treatment of brain tumors 
PDT has been investigated as an adjuvant for the treatment of malignant gliomas for approximately 
35 years (Quirk et al. 2015). Although numerous clinical trials have been initiated, the vast 
majority have consisted of uncontrolled phase I/II studies. Due to differences in methodology and 
types of malignant brain tumors treated, it has been very difficult to evaluate PDT efficacy from 
these limited trials. In order for PDT to gain widespread clinical acceptance, it must demonstrate 
outcomes similar to, and hopefully better, than those achievable with the current standard of care 
consisting of surgical resection + radiation + temozolomide which results in a median overall 
survival of 14.6 months and median progression free survival of 6.9 months for newly diagnosed 
GBM (Stupp et al. 2005). 
In a large phase I/II clinical trial conducted in Melbourne, newly diagnosed GBM patients were 
treated with high light dose PDT (240 J cm-2) using a first generation photosensitizer (Stylli et al. 
2005). Mean overall survival (14.3 months) compared favorably with the current standard of care. 
The results of a clinical trial involving 112 patients with newly diagnosed GBM in Toronto were 
rather disappointing (mean overall survival of 7.6 months)(Muller and Wilson 2006). The modest 
results were likely due to the low light dose used (58 J cm-2). Additional trials involving both 
newly diagnosed and recurrent GBM patients in Munich (Beck et al. 2007), Innsbruck (Beck et al. 
2007) and Dundee (Eljamel, Goodman, and Moseley 2008) have failed to show substantial 
improvements in both overall survival and progression free survival compared to the standard of 
care. Results of two recent small scale PDT trials in Japan were rather encouraging (Akimoto, 
Haraoka, and Aizawa 2012; Muragaki et al. 2013) as they demonstrated significant improvement 
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in both overall survival and progression free survival in newly diagnosed and recurrent GBMs. 
The same approach, consisting of a new generation photosensitizer (talaporfin sodium) in 
combination with spot irradiation of the resection margins, was used in both trials.  
 Overall, the results of PDT trials for malignant gliomas have been relatively modest thus 
providing the rationale for alternative treatment approaches such as PCI.    
1.4 Photochemical Internalization  
Photochemical Internalization (PCI) is a modified form of PDT which has been used to enhance 
the uptake of a wide variety of macromolecules including proteins, genes, oligonucleotides and 
chemotherapeutic agents such as bleomycin (Table 3). The PCI process is illustrated in Figure 4. 
As shown in panel A, many macromolecules enter cells via endocytosis, which results in their 
encapsulation in endosomes. 
 
Figure 4 The PCI process (Moses and You 2013). 
In order to exert their therapeutic effect, macromolecules must be released from the endosomes 
into the cytosol where they can diffuse to the target (typically the DNA). Unfortunately, only a 
small fraction of macromolecules escape the endosomes prior to endosome-lysosome fusion which 
results in the degradation of the macromolecule thus rendering them ineffective. In PCI (panel B), 
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a membrane localizing photosensitizer is administered prior to administration of the therapeutic 
macromolecule. Following endocytosis, the photosensitizer laden endosome walls are exposed to 
light and the resultant PDT effect ruptures the membranes thus releasing the macromolecules into 
the cytosol prior to endosome-lysosome fusion, this process is known as the “light after” approach 
(Weyergang et al. 2011).  
 
Table 3 Summary of macromolecules used in PCI. 
Uterus cancer In vitro
TPPS4,TPPS2a
AlPcS2a,TPCS2a
Doxorubicin,Gelonin 
Cetuximab-Saporin
(Pål Kristian Selbo, Sandvig, et al. 2000)
(Olsen et al. 2013)
(Wai et al. 2007)
Head and Neck 
cancer
In vitro
tetraphenyl porphine
AlPcS2a
TPPS2a
Ranpirnase
Saporin
PAMAM‐saporin
(Liebers et al. 2017)
(Lai et al. 2008)
(Wang et al. 2012)
Breast cancer In vitro
TPPS2a,TPCS2a
AlPcS2a
EGF-saporin, Doxorubicin
Gelonin, IM7-saporin
(Pål Kristian Selbo et al. 2012)
(Olsen et al. 2013)
(Bostad et al. 2014)
In vivo DPc,TPCS2a
(DPc/m) Doxorubicin
scFvMEL-rGel
(Lu et al. 2011)
(Eng et al. 2018)
Colon cancer In vitro
TPPS2a
AlPcS2a
TPCS2a
MOC31‐gelonin,
Trastuzumab–saporin
Cetuximab−saporin
(Pål Kristian Selbo, Sivam, et al. 2000)
(Berstad, Weyergang, and Berg 2012)
(Wai et al. 2007)
In vivo AlPcS2a
Bleomycin
Gelonin 
(Pl Kristian Selbo et al. 2001)
(Pl Kristian Selbo et al. 2001)
Ovarian cancer In vitro TPPS2a
EGF–saporin
(liposomally encapsulated 
saporin)
(Weyergang, Selbo, and Berg 2006)
(Fretz et al. 2007)
Sarcoma In vitro
TPCS2a,AlPcS2a
TPPS2a
IM7-saporin
Gelonin 
(Bostad et al. 2014)
(Dietze et al. 2003)
In vivo AlPcS2a
Bleomycin
Gelonin
(O.-J. Norum, Giercksky, and Berg 2009)
(Berg et al. 2005)
Bladder cancer In vitro
TPCS2a
TPPS2a,AlPcS2a
Bleomycin
scFvMEL/rGel
(Arentsen et al. 2014)
(Pål K. Selbo et al. 2009)
In vivo TPCS2a Bleomycin (Gederaas et al. 2017)
Glioma In vitro AlPcS2a
Doxorubicin
Bleomycin
(Shin et al. 2018)
(Mathews et al. 2012)
In vivo AlPcS2a Bleomycin,ETXp (Hirschberg et al. 2009)
Skin cancer In vitro
TPPS2a
AlPcS2a
Cetuximab−saporin
Gelonin
(Wai et al. 2007)
(Prasmickaite et al. 2002)
In vivo AlPcS2a, TPPS2a scFvMEL/rGel (Pål K. Selbo et al. 2009)
Prostate cancer In vitro TPPS2a
cetuximab−saporin
IM7-saporin
(Wai et al. 2007)
(Bostad et al. 2014)
Pancreatic cancer In vitro TPCS2a
IM7-saporin
anti-CD133
(Bostad et al. 2014)
(Bostad et al. 2013)
Lung cancer In vitro AlPcS2a, 3‐THPP
2 MOC31‐gelonin (Pål Kristian Selbo, Sivam, et al. 2000)
Cancer type In vivo/In vitro Photosensitizer Cytotoxic agents References
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1.5 Cell line  
F98 rat glioma cells were used in this study (Figure 5). The cells were originally derived from 
transformed fetal Fischer rat brain cells following exposure to a known carcinogen (ethyl-
nitrosourea) (Ko, Koestner, and Wechsler 1980). The F98 cell line has been used in a number of 
in vitro and in vivo studies evaluating the effects of a variety of therapeutic modalities including 
PDT (Madsen, Kharkhuu, and Hirschberg 2007). The cell line shares many characteristics with 
human GBM including infiltrative behavior and rapid proliferation. Furthermore, when F98 cells 
are implanted into brains of Fischer rats, tumors develop rapidly and are highly reproducible from 
animal to animal. The weak immunogenicity of F98 tumors is a substantial advantage over other 
rat glioma cell lines which have been shown to evoke strong immune responses (Barth and Kaur 
2009).  
 
Figure 5 F98 rat glioma cells (ATCC 2016). 
1.6 Spheroids 
The majority of in vitro therapeutic studies have been conducted on cells arranged in monolayers 
since this is an easy model to maintain. In this configuration, all cells have adequate access to 
nutrients and oxygen in the cell medium. Unfortunately, monolayers do not mimic the three-
dimensional nature of solid tumors and the resultant nutrient and oxygen gradients affect 
therapeutic response, especially for oxygen-mediated therapies such as ionizing radiation and 
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PDT. Spheroids are three-dimensional cell clusters that closely resemble the tumor environment 
(Santini, Rainaldi, and Indovina 2000). Of particular relevance to this work is the ability of 
multicellular spheroids to mimic the oxygen gradients found in tumors. As shown in Figure 6, as 
spheroids grow beyond a diameter of 250 - 300 µm diameter, a central core of necrosis develops 
due to the limited diffusion of oxygen from its source (Dubessy et al. 2000).  
 
Figure 6 Three-dimensional spheroid consisting of F98 cells illustrating the characteristic cell viability zones, modified from 
(LaBonia et al. 2016) 
Although cells in the necrotic core are dead and therefore not of relevance in therapeutic studies, 
cells adjacent to the necrotic core are hypoxic and therefore resistant to PDT. Due to the lack of 
oxygen, these cells are not proliferating and are therefore found in the quiescent (G0) stage of the 
cell cycle. As in solid tumors, these resistant cells are treatment limiting. The outermost layer of 
cells in the spheroid are in a relatively oxygen rich environment as they are closest to the source 
of oxygen, i.e., the medium and therefore they proliferate rapidly. In addition to the oxygen 
gradients, spheroids are also capable of mimicking photosensitizer gradients found in tumors 
including the effects of the extracellular matrix which may impede diffusion of the sensitizer. Since 
spheroid diameters were approximately 250 – 300 µm at the time of laser irradiation, light 
distributions were relatively uniform throughout the spheroid.  
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Although the lack of a vasculature is a drawback of the spheroid model it may be possible to 
address this limitation by placing spheroids on the surface of the developing chick embryo. For 
example, De Magalhães et al. 2010 found significant vascularization of human glioma spheroids 
7 days following implantation on the chick chorioallantoic membrane. 
1.7 5-Fluorouracil 
A number of chemotherapeutic agents have been used in the treatment of GBM. Ideally these drugs 
should have the ability to cross the blood-brain barrier followed by entry into cells through the 
plasma membrane. This typically occurs only for low molecular weight and/or lipophilic drugs via 
passive diffusion across the cell membrane (Mathews et al. 2012). Unfortunately, many 
chemotherapeutic drugs are large and hydrophilic thus requiring active transport into cells via 
endocytosis (Zaniboni, Prabhu, and Audisio 2005). As discussed previously, PCI may be used to 
enhance the efficacy of these macromolecules. In the majority of studies reported to date, PCI has 
been used to enhance the efficacy of bleomycin – a 1.5 kDa glycopeptide antibiotic that causes 
single and double strand DNA breaks similar to the damage caused by ionizing radiation. PCI has 
been shown to enhance the efficacy of bleomycin in a number of different cell lines including 
gliomas (Madsen et al. 2009). 5-Flurouracil (5-FU) is an antimetabolite (Figure 7) that has received 
FDA approval for the treatment of a wide variety of cancers including colon, rectal, breast, head 
and neck, cervical and a number of gastrointestinal tumors.(Longley, Harkin, and Johnston 2003). 
5-FU acts primarily as a thymidylate inhibitor. Inhibition of this enzyme blocks synthesis of 
pyrimidine thymidine which is required for DNA replication. Ultimately, administration of 5-FU 
results in preferential death of rapidly dividing cancer cells. Other mechanisms of action include 
the downregulation of various RNA processes and activation of the tumor suppressor gene, p53 
resulting in apoptotic cell death.(Longley, Harkin, and Johnston 2003). 5-FU is a small molecule 
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(130 Da) that enters the cytoplasm via passive diffusion. Nevertheless, a recent study has shown 
that PDT and 5-FU interact in a synergistic manner akin to that observed with PCI (Christie et al. 
2017).  
 
Figure 7 Molecular structure of 5-FU (He et al. 2015). 
1.8 Photosensitizer 
The photosensitizer used in this work, AlPcS2a, is a phthalocyanine derivative containing two 
charged sulfonate groups linked to phthalic subunits in adjacent positions and an aluminum metal 
ion incorporated at its center (Figure 8). Of particular relevance to PCI is that AlPcS2a is an 
amphiphilic molecule, i.e., it has both hydrophilic and lipophilic properties and therefore it 
localizes in cellular membranes following systemic administration (Hirschberg and Madsen 2017). 
The lipophilic phthalocyanine skeleton of AlPcS2a localizes in the lipophilic interior of the cellular 
membrane while the sulfonate groups dissolve in the hydrophilic outer layer of the membrane. 
 
Figure 8 Molecular structure of AlPcS2a (Pål Kristian Selbo et al. 2002). 
13 
 
1.9 Scope of Work 
The purpose of this work was to determine the efficacy of combined 5-FU and AlPcS2a-PDT in an 
in vitro model consisting of three-dimensional multicell F98 glioma spheroids. Specifically, 
different wash protocols were investigated to determine whether any observed interaction between 
the two treatments could be attributed to the PCI mechanism, or was simply due to different 
cytotoxic pathways of the two modalities.   
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MATERIALS AND METHODS 
2.1 Maintenance of Cell Line 
All experiments were done at the University of Nevada, Las Vegas. The F98 rat glioma cell line 
used in this experiment was propagated in T-25 BD Falcon flasks with a vented cap and the media 
used was Dulbecco’s Modified Eagle Medium (DMEM, Thermo Fisher Corp., Carlsbad CA) 
modified with 15 ml of HEPES, 5 ml of Pen-Strep (10,000 units/ml Penicillin, 10,000 µg/ml 
Streptomycin, Thermo Fisher Corp., Carlsbad CA) and 50 ml of fetal bovine serum (FBS; Thermo 
Fisher Corp., Carlsbad CA). Cells were kept in an incubator at the following settings: 37°C, 5% 
CO2, 80% humidity. The protocol to culture the cells was as follows: at cell confluence, the 
medium was removed and the adherent F98 monolayer was washed using 5-7 ml of phosphate 
buffer solution (PBS; Thermo Fisher Corp, Carlsbad CA). Following PBS removal, the monolayer 
was treated with 5 ml of Gibco Trypsin-EDTA for five minutes. The detached cells were then used 
to make spheroids.  
2.2 Creation of Spheroids 
Following cell detachment, PBS (7-10 ml) was added to the cells and the resultant solution was 
transferred to a 15 ml centrifuge tube which was placed into a centrifuge and spun at a setting of 
400 g for 4 minutes. Following centrifugation, the cells formed a pellet at the bottom of the tube. 
The excess PBS was removed, replaced with fresh PBS and vortexed. This process was then 
repeated. Media was then added instead of PBS followed by vortexing to disperse the pellet. Cells 
were counted using a C-Chip (SKC Inc., Covington CA). The spheroids were generated using a 
total of 12000 cells per ml. The cells in 100 µl of medium were alloquated into individual wells of 
a Costar 96 well round bottom ultra-low attachment plate (Fisher Scientific, Inc., Pittsburgh PA), 
centrifuged at 400 g for 4 min. and placed in an incubator for 45-60 min. Following incubation, 
the plate was then centrifuged a second time at 800 g for 8 min. Cells in each well were visually 
15 
inspected using a microscope to confirm a disc shaped appearance. The plate was placed in the 
incubator (37°C, 5% CO2, 80% humidity) for 48 h to allow the spheroids to assume their 
characteristic 3-D shape. In the case of the PCI experiments, five plates were centrifuged: dark 
controls, PDT controls, and 3 PCI experimental plates. In all cases, the mean spheroid diameter 
prior to the initiation of treatment was 250 – 300 µm. 
2.3 5-FU Procedure 
Five mg/ml of 5-FU in DMSO was diluted to a 1 mg/ml stock solution with PBS. The stock 
solution was then diluted with DMEM to the following concentrations: 0.25, 0.5 and 1 µg/ml. 
Controls (0 µg/ml) consisted of spheroids in DMEM only. Two days following creation, spheroids 
were incubated in various 5-FU concentrations. Each well consisted of 200 µl 5-FU-DMEM 
solution (or DMEM in the case of controls) which was replaced with new medium 5 days following 
incubation and, as such, spheroids were incubated with various concentrations of 5-FU for 5 days. 
2.4 Laser Setup 
The setup for laser irradiation is shown in Figure 9. Spheroids were irradiated with a 670 nm diode 
laser (Intense, North Brunswick NJ) coupled to a 200 µm dia. optical fiber (Medlight SA, 
Ecublens, Switzerland). A ring stand was used in combination with a cardboard cutout which 
allowed the plates to be elevated above the laser thus facilitating spheroid irradiation from the 
bottom of the plate. The cardboard cutout ensured irradiation of only three columns at a time. In 
all cases, spheroids were irradiated with a 9 cm dia. beam at an irradiance of 5 mW/cm2 for 60, 
120, or 200 s corresponding to radiant exposures of 0.3, 0.6, or 1.0 J cm-2, respectively. On a given 
plate, each irradiated group was separated by two empty columns in order to minimize the effects 
of light scattering and its contribution to light dose to spheroids in the other radiant exposure 
groups.  
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Figure 9 Experimental setup showing laser irradiation of 96-well plate. 
2.5 Photodynamic Therapy Procedure 
Forty-eight hours following centrifugation, spheroids were examined with a light microscope to 
ensure their characteristic 3D shape prior to PDT treatments. The photosensitizer AlPcS2a (Frontier 
Scientific, Inc., Logan UT) was diluted to a concentration of 2 µg/ml with DMEM and 100 µL of 
this solution was added to each spheroid in the 96 well plate (one spheroid per well). The plate 
was covered with aluminum foil to minimize background light exposure and placed in an incubator 
for 18 h. Following incubation, the photosensitizer was removed from each well using a wash 
protocol consisting of replacing the photosensitizer solution with 100 µl PBS. A total of four 
washes were performed to ensure complete removal of the sensitizer. The spheroids were then 
irradiated either immediately following the wash cycle (0 h protocol), 4 h later (4 h protocol), or 
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24 h later (24 h protocol) according to the light protocols described in section 2.4. Following PDT 
treatments, the plates were placed in an incubator for 48 h after which the first spheroid volumes 
were recorded. All procedures described in this section were performed under subdued light 
conditions in order to minimize the possibility of ambient light-induced PDT toxicity.  
2.6 Combined PDT + 5-FU Procedure 
Except for the addition of 5-FU, the combined treatment protocol was identical to the PDT 
procedure described in Section 2.5. 5-FU was diluted with DMEM to a concentration of 0.25 µg/ml 
and 100 ul of this solution was added to each well containing a PDT + 5-FU-designated spheroid. 
In the case of the 0 h protocol, spheroids were irradiated immediately following the addition of 5-
FU. For the four hour protocol, spheroids were irradiated 4 h after 5-FU incubation. This is the 
standard PCI protocol employing bleomycin. In the case of the 24 h protocol, 5-FU was added 24 
h after the last wash followed immediately by light irradiation. The three protocols are summarized 
below.  
0 h Protocol 
 
                18 h AlPcS2a incubation → wash → wash → wash → wash --- 5-FU → light 
 
4 h Protocol 
 
                18 h AlPcS2a incubation → wash → wash → wash → wash → 5-FU -- 4 h → light 
 
24 h Protocol 
 
            18 h AlPcS2a incubation → wash → wash → wash → wash → 24 h → 5-FU ---light 
 
Following light exposure, the plates were placed in an incubator for 48 h after which the first 
spheroid volume measurements were made. 
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2.7 Measurements and Analysis 
In all cases, treatment efficacy was determined from spheroid growth kinetics. A light microscope 
with a calibrated eyepiece was used to measure spheroid diameters. For each spheroid, the mean 
of two diameter measurements (vertical and horizontal) were recorded and the volume calculated 
assuming a perfect sphere. Spheroids (12 per experimental group) were followed for 
approximately two weeks. Spheroids were measured 5, 8, 10 and 13 days following treatment and 
normalized spheroid volume was plotted to determine treatment efficacy. Normalized volume was 
determined by calculating the ratio of volumes of treated to untreated controls on the last 
measurement day. In order to determine the degree of interaction between PDT and 5-FU, the 
following equation was used (Drewinko et al. 1976): 
𝛼 =
𝑉𝑃𝐷𝑇 ∗ 𝑉  5−𝐹𝑈
𝑉𝑃𝐷𝑇+5−𝐹𝑈
 
where VPDT, V5-FU and VPDT+5-FU represent normalized volumes of spheroids subjected to PDT, 5- 
FU and PDT + 5-FU. In this scheme, an alpha value of one represents an additive effect while 
alpha values less than or greater than one represent antagonistic or synergistic effects respectively. 
Student t-tests were performed to determine whether the results of the different wash protocols 
were statistically significant (www.graphpad.com).    
  
19 
 
RESULTS 
3.1 5-FU dose dependence 
The effects of 5-FU on F98 spheroids are shown in Figure 10. Normalized spheroid volumes 
ranged from 0.72 at the lowest 5-FU concentration investigated (0.12 µg/ml), to 0.17 at the highest 
concentration (0.5 µg/ml). Based on these results, a concentration of 0.12 µg/ml 5-FU was used 
for all subsequent PCI studies. The rationale for this choice is based on the objective of PCI which 
is to enhance the effects of therapeutic drugs at relatively low concentrations.   
 
Figure 10 Effects of 5-FU on F98 spheroid growth. Spheroids were incubated in varying concentrations of 5-FU for 5 days. 
Normalized spheroid volumes were recorded 13 days following the start of incubation. Each data point represents the mean of 6 
trials (12 spheroids per trial) and error bars represent standard deviations 
3.2 PDT results 
The effects of PDT on spheroid growth are illustrated in Figure 11 for three different wash 
protocols. The purpose of the wash was to remove excess photosensitizer from the wells prior to 
light irradiation. In standard PDT protocols, spheroids are irradiated immediately following the 
wash cycle, i.e., the 0 h protocol (Figure 11a). The data in Figure 11a show a moderate PDT dose 
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response ranging from 0.86 ± 0.06 at a radiant exposure of 0.3 J cm-2 to 0.69 ± 0.07 at 1.0 J cm-2. 
A similar dose response was observed for spheroids subjected to PDT after a 4h wash protocol 
(Fig. 11b) where normalized volumes ranged from 0.97 ± 0.08 for spheroids exposed to 0.3 J cm-
2, to 0.73 ± 0.09 following exposures to 1.0 J cm-2. PDT-treated spheroids subjected to the 24 h 
wash protocol demonstrated only a marginal response ranging from 1.03±0.04 for 0.3 J cm-2 to 
0.89 ± 0.04 for a radiant exposure of 1.0 J cm-2 (Figure 11c). As evidenced from the student t-tests 
summarized in Table 4, statistical significance was demonstrated in most cases. Overall, the data 
suggest that the 0 h wash protocol was the most effective for inhibiting spheroid growth while the 
24 h protocol was the least effective. 
p < 0.05 is considered statistically significant 
Table 4 Evaluation of statistical significance for different wash protocols 
 
 
 
0 h vs. 4 h 4 h vs. 24 h 
Radiant Exposure    
(J cm-2) 
p-value Radiant Exposure    
(J cm-2) 
p-value 
0.3 0.024 0.3 0.139 
0.6 0.040 0.6 0.004 
1.0 0.317 1.0 0.001 
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Figure 11 PDT effects on F98 glioma spheroids subjected to three different wash protocols. Normalized spheroid volumes were 
recorded 13 days following light exposure. Each data point represents the mean of 6 trials (12 spheroids per trial) and error bars 
represent standard deviations.  
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3.3 PDT + 5-FU results 
Results of the combined experiments are summarized in Figure 12. Significant treatment effects 
were observed for spheroids subjected to the 0 and 4 h wash protocols. For example, normalized 
volumes for 0 h spheroids ranged from 0.60±0.04 (0.3 J cm-2) to 0.35±0.04 (1.0 J cm-2) while 
normalized volumes for the 4 h spheroids ranged from 0.65±0.04 (0.3 J cm-2) to 0.40±0.03 (1.0 J 
cm-2). In both cases, the greatest effect was observed at the highest radiant exposure. In contrast,
treatment efficacy was observed to be lower for 24 h spheroids (Figure 12c) which showed no 
dependence on radiant exposure (0.68±0.04 for 0.3 J cm-2 and 0.64±0.02 for 1.0 J cm-2). In order 
to obtain a quantitative measure of the degree of interaction between the two treatment modalities, 
alpha values were calculated from equation (1) and summarized in Table 5. The data show a 
marginal synergistic effect at the highest radiant exposure for both 0 and 4 h spheroids. In all other 
cases, α ~ 1.0 suggesting an additive effect between PDT and 5-FU. 
Radiant Exposure 
(J cm-2) 
0 h 4 h 24 h 
0.3 1.03±0.10 1.10±0.12 1.11±0.08 
0.6 1.18±0.15 1.15±0.14 1.01±0.06 
1.0 1.42±0.22 1.35±0.19 1.02±0.06 
Table 5 Alpha values for different wash protocols 
Spheroid growth kinetics for one trial of each of the three wash protocols are shown in Figure 13 
A-C. Not surprisingly, the data show that the PDT + 5-FU protocols result in the greatest growth
inhibition. The PDT effect for spheroids subjected to the 24 h wash protocol was marginal 
compared to the 0 and 4 h spheroids.  
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Figure 12 Effects of combined PDT and 5-FU on F98 glioma spheroids subjected to three different wash protocols. Normalized 
spheroid volumes were recorded 13 days following light exposure. Each data point represents the mean of 4 trials (12 spheroids 
per trial) and error bars represent standard deviations 
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Figure 13 Growth kinetics of F98 glioma spheroids subjected to three different wash protocols. In each case, treatment was initiated 
on day 0. Each data point represents the mean of 12 spheroids. Standard deviations were too small to plot. 
0
0.1
0.2
0.3
0.4
0 2 4 6 8 10 12 14
V
o
lu
m
e
 (
m
m
3
)
Day
0 h Protocol
Control
DC
0.3 J + 5-FU
0.6 J + 5-FU
1 J + 5-FU
0.3 J-CONTROL
0.6 J-CONTROL
1 J-CONTROL
5-FU
A
0
0.1
0.2
0.3
0.4
0.5
0 2 4 6 8 10 12 14
V
o
lu
m
e
 (
m
m
3
)
Day
4 h Protocol
Control
DC
0.3 J + 5-FU
0.6 J + 5-FU
1 J + 5-FU
0.3 J-CONTROL
0.6 J-CONTROL
1 J-CONTROL
5-FU
B
0
0.1
0.2
0.3
0.4
0.5
0.6
0 2 4 6 8 10 12 14 16
V
o
lu
m
e
 (
m
m
3
)
Day
24 h Protocol
Control
DC
0.3 J + 5-FU
0.6 J + 5-FU
1 J + 5-FU
0.3 J-CONTROL
0.6 J-CONTROL
1 J-CONTROL
5-FU
C
25 
 
DISCUSSION 
PCI is a type of PDT that has been shown to enhance the efficacy of a wide variety of hydrophilic 
macromolecules with limited ability to cross the cell membrane (Weyergang et al. 2011). PCI has 
been demonstrated in a wide variety of cell lines and in vivo models (Pål Kristian Selbo et al. 
2010). Results from the first clinical PCI trial suggest that it may be a useful therapeutic approach 
for head and neck cancer patients who have failed standard treatments (Sultan et al. 2016). A 
number of in vitro studies employing 3-D multicell glioma spheroids suggest that PCI may be 
useful for the delivery of large chemotherapeutic drugs, such as bleomycin, to patients with 
malignant brain tumors (Mathews et al. 2012). Bleomycin is a large hydrophilic molecule that 
enters the cytosol via endocytosis. In traditional in vitro PCI protocols employing bleomycin, cells 
or spheroids are incubated with a membrane-localizing photosensitizer (e.g. AlPcS2a) for 18 h 
followed by 4 h incubation with bleomycin. The 4 h incubation, allows a sufficient amount of the 
drug to be internalized in endosomes within the cytosol.  
Small lipophilic molecules, such as 5-FU, enter the cytosol via passive diffusion across the plasma 
membrane and, as such, is not ideally suited for PCI. A recent study showed that PDT enhanced 
the efficacy of 5-FU in a synergistic manner in F98 spheroids (Christie et al. 2017). The reason for 
the synergism was unknown, but was likely due to an interaction between PDT and 5-FU, rather 
than a PCI effect. The thesis experiments, consisting of different wash protocols, were designed to 
resolve this issue. A true PCI effect between PDT and 5-FU should be manifested by greater 
spheroid growth inhibition following the 4 h wash protocol. If the 0 and 4 h wash protocols produce 
similar growth inhibition, a non-PCI interaction between PDT and 5-FU is the likely explanation.   
 Based on the 5-FU dose response data (Figure 10), the potency of this drug is 
approximately five times greater than bleomycin. For example, the 5-FU dose required for a 50% 
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reduction in F98 spheroid volume is approximately 0.2 µg/ml. A similar reduction in spheroid 
volume was observed following a bleomycin dose of approximately 1 µg/ml (Gonzales et al. 
2016). 
 The PDT dose response data (Figure 11) is in good agreement with previous studies 
employing identical spheroids (Christie et al. 2017). For example, Christie et al. observed 
normalized spheroid volumes of 85-90% following PDT at a radiant exposure of 0.8 J cm-2. This 
compares favorably with the normalized volumes observed for the 0 h PDT protocol (77% at 0.6 
J cm-2 and 69% at 1.0 J cm-2). Overall, the data show that PDT efficacy was greatest when 
spheroids were irradiated immediately following AlPcS2a incubation (0 h protocol) and least 
effective if a 24 h interval was inserted following incubation (24 h protocol). This is not surprising 
since one would expect an increasing amount of photosensitizer to diffuse out of the plasma 
membrane with time and therefore less AlPcS2a to be available for the PDT effect after 24 h 
compared to 0 or 4 h.  
 The combination of PDT and 5-FU produced an enhanced growth effect compared to that 
observed for either modality alone (Figure 12). Although slight differences in normalized spheroid 
volumes were observed between 0 and 4 h protocols, none were found to be statistically significant. 
This suggests that the observed effect was likely not due to PCI. The similar results obtained for 
the two wash protocols suggest that 5-FU enters the cytosol via passive diffusion rather than by 
endocytosis which is a requirement for PCI. The calculated alpha values (Table 5) corroborate this 
conclusion. Based on the alpha values, a synergistic response was observed only for 0 (α = 
1.42±0.22) and 4 (1.35±0.19) h spheroids subjected to the highest light exposure. This is a marginal 
synergistic response compared to previous PCI studies with bleomycin where alpha values are 
typically in the 2-3 range (Mathews et al. 2012). In all other cases, alpha values were 
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approximately unity suggesting a simple additive effect between PDT and 5-FU. Unlike the 0 and 
4 h wash protocols, no light dose dependence was observed for the 24 h spheroids, in fact, 
normalized volumes for the combined PDT and 5-FU treated spheroids were essentially identical 
to the 5-FU only treated spheroids suggesting that the observed effect was almost entirely due to 
5-FU. This is consistent with the hypothesis that the photosensitizer had leached out of the plasma 
membrane thus negating the PDT effect.  
 Overall, the data suggest that there is no PCI effect with 5-FU and therefore the weak 
synergism observed is likely due to different mechanisms of action of PDT and 5-FU. In contrast 
to 5-FU, which inhibits RNA transcription and DNA synthesis (Tiraby et al. 1998), AlPcS2a-PDT 
is known to cause damage to the plasma membrane as well as membranes of organelles, such as 
lysosomes resulting in hydrolase release and cell death via apoptosis (Guicciardi, Leist, and Gores 
2004; Kessel, Vicente, and Reiners 2006; Rodriguez et al. 2009) or autophagy (Inguscio, 
Panzarini, and Dini 2012; Reiners et al. 2010).     
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CONCLUSIONS 
5-FU was found to be a potent cytotoxic agent in the F98 glioma spheroid model and, as such, 
only very low concentrations were required for the combined studies investigated in this work. 
The PDT dose response was in good agreement with the findings of other studies using identical 
spheroids. Not surprisingly, PDT was most efficient following 0 or 4 h wash protocols compared 
to 24 h protocols. The combination of PDT and 5-FU was more effective than either treatment 
alone, however, no statistically significant differences were observed between the 0 and 4 h wash 
protocols suggesting that the observed effects were likely due to different cytotoxic pathways of 
PDT and 5-FU. Furthermore, the results are consistent with findings that 5-FU enters the cytosol 
via passive diffusion as opposed to endocytosis which is a requirement for PCI. 
Future studies could be performed to elucidate the different mechanisms of AlPcS2a-PDT and 5-
FU in this cell line. AlPcS2a is a membrane localizing photosensitizer found primarily in the plasma 
membrane, and to a lesser extent, in membranes of internal organelles such as lysosomes. 
Therefore, the type of cell death following light irradiation (PDT) is likely dependent on the wash 
protocol. For example, if spheroids are irradiated immediately following the wash (0 h protocol), 
necrosis is expected to be the dominant mode of cell death due to damage to the plasma membrane. 
Some lysosomal damage is also expected, resulting in apoptotic cell death. In contrast, apoptosis 
is expected to be much more prevalent in spheroids subjected to the 4 h wash protocol since the 
photosensitizer leaches out of the plasma membrane (while remaining in the lysosome membrane) 
during the 4 h interval. One would thus expect a shift from necrotic to apoptotic cell death. The 
mode of PDT-induced cell death in response to different wash protocols could be examined by 
using commercially available assays for necrosis and apoptosis. 
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